INGN vs LUNG vs MDT vs HOLX vs BDX

For growth investors, Becton, Dickinson and Company (BDX) is the stronger pick with 8.

2% revenue growth year-over-year, versus 1. 7% for Hologic, Inc. (HOLX). Medtronic plc (MDT) offers the better valuation at 21. 1x trailing P/E (13. 8x forward), making it the more compelling value choice. Analysts rate Inogen, Inc. (INGN) a "Buy" — based on 11 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Medtronic plc (MDT) is the cheapest at 21.

1x versus Hologic, Inc. at 30. 5x. On forward P/E, Becton, Dickinson and Company is actually cheaper at 11. 9x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Becton, Dickinson and Company wins at 0. 72x versus Medtronic plc's 35. 17x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, Hologic, Inc.

(HOLX) delivered a total return of +16. 8%, compared to -96. 8% for Pulmonx Corporation (LUNG). Over 10 years, the gap is even starker: HOLX returned +124. 3% versus LUNG's -96. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Medtronic plc (MDT) is the lower-risk stock at 0.

42β versus Pulmonx Corporation's 2. 31β — meaning LUNG is approximately 444% more volatile than MDT relative to the S&P 500. On balance sheet safety, Inogen, Inc. (INGN) carries a lower debt/equity ratio of 9% versus 104% for Pulmonx Corporation — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Becton, Dickinson and Company (BDX) is pulling ahead at 8.

2% versus 1. 7% for Hologic, Inc. (HOLX). On earnings-per-share growth, the picture is similar: Inogen, Inc. grew EPS 44. 1% year-over-year, compared to -25. 0% for Hologic, Inc.. Over a 3-year CAGR, LUNG leads at 19. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Medtronic plc (MDT) is the more profitable company, earning 13.

9% net margin versus -59. 7% for Pulmonx Corporation — meaning it keeps 13. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MDT leads at 17. 8% versus -59. 3% for LUNG. At the gross margin level — before operating expenses — LUNG leads at 74. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Becton, Dickinson and Company (BDX) is the more undervalued stock at a PEG of 0. 72x versus Medtronic plc's 35. 17x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Becton, Dickinson and Company (BDX) trades at 11. 9x forward P/E versus 17. 2x for Hologic, Inc. — 5. 3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for INGN: 270. 4% to $26. 00.

In this comparison, MDT (3.

7% yield), BDX (2. 8% yield) pay a dividend. INGN, LUNG, HOLX do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Medtronic plc (MDT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

42), 3. 7% yield). Pulmonx Corporation (LUNG) carries a higher beta of 2. 31 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (MDT: +24. 3%, LUNG: -96. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: INGN is a small-cap quality compounder stock; LUNG is a small-cap quality compounder stock; MDT is a mid-cap income-oriented stock; HOLX is a mid-cap quality compounder stock; BDX is a mid-cap quality compounder stock. MDT, BDX pay a dividend while INGN, LUNG, HOLX do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.